Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C

Journal of Hepatology

Volumn 61, Issue 1, 2014, Pages S91-S97

  Kumar, Sonal ^a   Jacobson, Ira M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hepatitis C; Nucleoside nucleotide polymerase inhibitors; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; NONSTRUCTURAL PROTEIN 5B; NUCLEOTIDE POLYMERASE INHIBITOR; PEGINTERFERON; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; NUCLEIC ACID SYNTHESIS INHIBITOR; URIDINE PHOSPHATE; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE; VIRUS MUTATION; ANALOGS AND DERIVATIVES; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DNA, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; NUCLEIC ACID SYNTHESIS INHIBITORS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84913584398     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.09.006     Document Type: Review

References (49)

1. D. Lavanchy The global burden of hepatitis C Liver Int 29 2009 74 81
2. B. Hajarizadeh, J. Grebely, and G.J. Dore Epidemiology and natural history of HCV infection Nat Rev Gastroenterol Hepatol 10 2013 553 562
3. Global surveillance and control of hepatitis C J Viral Hepatol 6 1999 35 47
4. N.H. Afdhal The natural history of hepatitis C Semin Liver Dis 24 2004 3 8
5. M. Poenisch, and R. Bartenschlager New insights into structure and replication of the hepatitis C virus and clinical implications Semin Liver Dis 30 2010 333 347
6. T.K.H. Scheel, and C.M. Rice Understanding the hepatitis C virus life cycle paves the way for highly effective therapies Nat Med 19 2013 837 849
7. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, and R. Kauffman Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
8. P.Y. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, and D. Pound Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
9. C. Hézode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, and V. Canva Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
10. U. Koch, and F. Narjes Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase Curr Top Med Chem 7 2007 1302 1329
11. F. Legrand-Abravanel, F. Nicot, and J. Izopet New NS5B polymerase inhibitors for hepatitis C Expert Opin Investig Drugs 19 2010 963 975
12. R.K. Reddy, M. Rodriguez-Torres, E.J. Gane, R. Robson, J. Lalezari, and G.T. Everson Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy Hepatology 46 2007 862A
13. J. Lalezari, E. Gane, M. Rodriguez-Torres, E. DeJesus, D.R. Nelson, and G.T. Everson Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg BID for 28 days J Hepatol 48 2008 S29
14. E.J. Gane, M. Rodriguez-Torres, D.E. Nelson, I.M. Jacobson, J.G. McHutchison, and A. Duca Sustained virologic response (SVR) following RG7128 1500 mg BID/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders J Hepatol 52 2010 S16
15. E.J. Gane, S.K. Roberts, C.A.M. Stedman, P.W. Angus, B. Ritchie, and R. Elston Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
16. K. Gupta, M. Seifer, I. Serra, H. Rashidzadeh, S. Luo, and M. La Colla Favorable preclinical profile of Idx21437, a novel uridine nucleotide prodrug, for use in a direct-acting antiviral (DAA) regimen for HCV J Hepatol 60 2014 S504
17. M.P. Curry, X. Forns, R.T. Chung, N. Terrault, R.S. Brown, and J.M. Fenkel Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation Hepatology 58 2013 314A 315A
18. Z. Mariño, F. van Bömmel, X. Forns, and T. Berg New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C Gut 63 2014 207 215
19. J.J. Feld Interferon-free strategies with a nucleoside/nucleotide analogue Semin Liver Dis 34 2014 37 46
20. E. Lawitz, M. Rodriguez-Torres, J. Denning, M. Cornpropsr, D. Clemons, and L. Mcnair Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA
21. E.J. Gane, C.A. Stedman, R.H. Hyland, X. Ding, E. Svarovskaia, and W.T. Symonds Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44
22. K.V. Kowdley, E. Lawitz, I. Crespo, T. Hassanein, M.N. Davis, and M. DeMicco Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial Lancet 381 2013 2100 2107
23. E. Lawitz, J.P. Lalezari, T. Hassanein, K.V. Kowdley, F.F. Poordad, and A.M. Sheikh Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Lancet Infect Dis 13 2013 401 408
24. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
25. J.P. Lalezari, D.R. Nelson, R.H. Hyland, M. Lin, S.J. Rossi, and W.T. Symonds Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naïve patients with HCV infection: the QUANTUM study J Hepatol 58 2013 S346
26. A. Osinusi, E.G. Meissner, Y.-J. Lee, D. Bon, L. Heytens, and A. Nelson Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811
27. M.S. Sulkowski, M. Rodriguez-Torres, J. Lalezari, W.J. Fessel, K. Mounzer, and M.C. Shuhart All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1) Hepatology 58 2013 313A 314A
28. J. Guedj, H. Dahari, L. Rong, N.D. Sansone, R.E. Nettles, and S.J. Cotler Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc Natl Acad Sci USA 110 2013 3991 3996
29. R.J. Fontana, E.A. Hughes, and M. Bifano Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C Am J Transplant 13 2013 1601 1605
30. E.J. Gane, C.A. Stedman, R.H. Hyland, P.S. Pang, X. Ding, and W.T. Symonds All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study J Hepatol 58 2013 S6 S7
31. E. Lawitz, F.F. Poordad, P.S. Pang, R.H. Hyland, X. Ding, and H. Mo Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Lancet 383 2014 515 523
32. N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin, and M. Puoti Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
33. N. Afdhal, K.R. Reddy, D.R. Nelson, E. Lawitz, S.C. Gordon, and E. Schiff Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
34. E.J. Gane, R.H. Hyland, D. An, P.S. Pang, W.T. Symonds, and J.G. Mchutchison Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience J Hepatol 60 2014 S3 S4
35. K.V. Kowdley, S.C. Gordon, K.R. Reddy, L. Rossaro, D.E. Bernstein, and E. Lawitz Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
36. I.M. Jacobson, R. Ghalib, M. Rodriguez-Torres, Z. Younossi, A. Corregidor, and M.S. Sulkowski SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study Hepatology 58 2013 LB3
37. I.M. Jacobson, G.J. Dore, G.R. Foster, M.W. Fried, M. Radu, and V.V. Rafalsky Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial Lancet 384 2 2014 403 413
38. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
39. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, and M.S. Sulkowski Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
40. S. Zeuzem, G.M. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, and R.H. Hyland Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 2014 1993 2001
41. Lawitz E, Poordad F, Brainard D, Hyland RH, An D, Symonds WT, et al. Sofosbuvir in combination with PEGIFN and ribavirin for 12 weeks provides high SVR rates in HCV infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. In: 64th annual meeting of the American Association for the study of liver diseases; 2013. p. LB4.
42. R. Esteban, L. Nyberg, J. Lalezari, L. Ni, B. Doehle, and B. Kanwar Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy J Hepatol 60 2014 S4 S5
43. G.T. Everson, T.T. Tran, W.J. Towner, M.N. Davis, D. Wyles, and R. Nahass Safety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir + GS-5816 for 12 weeks in treatment naive patients with genotype 1-6 HCV infection J Hepatol 60 2014 S46
44. P.J. Ruane, D. Ain, R. Meshrekey, J. Riad, M. Soliman, and S. Mikhail Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naive and treatment-experienced patients with chronic genotype 4 HCV infection J Hepatol 60 2014 S503 S504
45. S.C. Gordon, W. Towner, A. Aggarwal, J. Ma, J. McNally, and L.M. Stamm Integrated safety analysis of sofosbuvir-based HCV treatment regimens from phase 3 studies Gastroenterology 146 2014 S921
46. A.M. Lam, C. Espiritu, S. Bansal, H.M. Micolochick Steuer, C. Niu, and V. Zennou Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus Antimicrob Agents Chemother 56 2012 3359 3368
47. E. Svarovskaia, H. Dvory-Sobol, V. Gontcharova, S. Chiu, C. Hebner, and R.H. Hyland Comprehensive resistance testing in patients who relapsed after treatment with sofosbuvir (GS-7977)-containing regimens in phase 2 studies Hepatology 56 2012 551A
48. A. Osinusi, M. Marti, K. Townsend, A. Nelson, A. Kohli, and R. Silk Retreatment of relapsers to sofosbuvir/ribavirin with sofosbuvir/ledipasvir: complete and rapid virologic suppression by week 4 J Hepatol 60 2014 S5 S6
49. Kohli A, Sims Z, Nelson A, Osinusi A, Tefari G, Pang P, et al. Combination oral, hepatitis C antiviral therapy for 6 or 12 weeks: final results of the SYNERGY trial. In: 21st conference on retroviruses and opportunistic infections; 2014. p. LB27.